modelS01XA24
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Cenegermin | |
| ATC code: | S01XA24 | route: | ocular |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
Cenegermin is a recombinant human nerve growth factor (rhNGF) approved for the treatment of neurotrophic keratitis, a rare degenerative disease affecting the cornea. It promotes corneal healing by supporting the survival and growth of corneal epithelial cells. Cenegermin is administered as ophthalmic eye drops and is currently approved and available for use in Europe and the United States.
Pharmacokinetics
No published pharmacokinetic parameters are available for cenegermin due to its topical ocular administration and large protein structure, which limits significant systemic absorption in humans. No data reported for different populations, as absorption into systemic circulation is considered negligible.
References
Yavuz Saricay, L, et al., & Fulton, AB (2023). Can Nerve Growth Factor (NGF) Be a Treatment Option for Pediatric Eye Diseases?. Seminars in ophthalmology 38(5) 427–432. DOI:10.1080/08820538.2023.2168485 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36683264
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)